Skip to content
Subscriber Only

Teva Falls Most in 21 Months on FDA Lovenox Approval

Teva Pharmaceutical Industries Ltd., the world’s biggest maker of generic drugs, fell the most in 21 months on concern sales of its Copaxone multiple sclerosis drug may decline if U.S. regulators approve rival medications.

The U.S. Food and Drug Administration on July 23 approved the marketing of generic versions of Sanofi-Aventis SA’s Lovenox anti-clotting drug from Novartis AG and Momenta Pharmaceuticals Inc. The decision may affect Copaxone because both drugs have a complex molecular structure, Natali Gotlieb, a Tel Aviv-based analyst at IBI, said today in an e-mailed report.